Insufficient scRNA-seq data for expression of CSNK2A3 at single-cell level.
Insufficient scRNA-seq data for expression of CSNK2A3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 88% | 5.92 | 1275 / 1445 | 69% | 1.36 | 126 / 183 |
ovary | 87% | 5.18 | 157 / 180 | 51% | 0.94 | 220 / 430 |
stomach | 80% | 4.41 | 287 / 359 | 47% | 1.01 | 134 / 286 |
lung | 97% | 10.14 | 558 / 578 | 18% | 0.32 | 210 / 1155 |
intestine | 86% | 5.92 | 829 / 966 | 23% | 0.41 | 120 / 527 |
skin | 95% | 8.85 | 1719 / 1809 | 6% | 0.08 | 27 / 472 |
brain | 78% | 5.05 | 2056 / 2642 | 21% | 0.42 | 150 / 705 |
breast | 90% | 6.45 | 413 / 459 | 8% | 0.11 | 84 / 1118 |
uterus | 95% | 6.45 | 162 / 170 | 2% | 0.04 | 10 / 459 |
thymus | 96% | 8.85 | 625 / 653 | 1% | 0.01 | 5 / 605 |
muscle | 95% | 10.70 | 764 / 803 | 0% | 0 | 0 / 0 |
bladder | 86% | 4.71 | 18 / 21 | 7% | 0.10 | 34 / 504 |
adipose | 91% | 7.11 | 1091 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 88% | 6.59 | 1180 / 1335 | 0% | 0 | 0 / 0 |
prostate | 87% | 5.56 | 214 / 245 | 1% | 0.01 | 5 / 502 |
adrenal gland | 87% | 5.55 | 224 / 258 | 1% | 0.01 | 3 / 230 |
kidney | 83% | 4.91 | 74 / 89 | 3% | 0.03 | 24 / 901 |
heart | 85% | 6.85 | 736 / 861 | 0% | 0 | 0 / 0 |
pancreas | 69% | 3.37 | 227 / 328 | 1% | 0.01 | 1 / 178 |
spleen | 69% | 2.88 | 166 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 61% | 5.79 | 567 / 929 | 0% | 0 | 0 / 0 |
liver | 59% | 2.73 | 134 / 226 | 0% | 0 | 0 / 406 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.03 | 1 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0045732 | Biological process | positive regulation of protein catabolic process |
GO_0018107 | Biological process | peptidyl-threonine phosphorylation |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_0006468 | Biological process | protein phosphorylation |
GO_0030307 | Biological process | positive regulation of cell growth |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0005956 | Cellular component | protein kinase CK2 complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0005515 | Molecular function | protein binding |
GO_0005524 | Molecular function | ATP binding |
Gene name | CSNK2A3 |
Protein name | Casein kinase II subunit alpha 3 (CK II alpha 3) (EC 2.7.11.1) (Casein kinase II alpha 1 polypeptide pseudogene) |
Synonyms | CSNK2A1P |
Description | FUNCTION: Probable catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Amplification-dependent oncogene; promotes cell proliferation and tumorigenesis by down-regulating expression of the tumor suppressor protein, PML. May play a role in the pathogenesis of the lung cancer development and progression. . |
Accessions | Q8NEV1 ENST00000528848.3 |